Publicaciones en colaboración con investigadores/as de Hospital de la Santa Creu i Sant Pau (9)

2024

  1. Novel risk loci for COVID-19 hospitalization among admixed American populations

    eLife, Vol. 13

2023

  1. A second update on mapping the human genetic architecture of COVID-19

    Nature

  2. Cloxacillin plus fosfomycin versus cloxacillin alone for methicillin-susceptible Staphylococcus aureus bacteremia: a randomized trial

    Nature Medicine, Vol. 29, Núm. 10, pp. 2518-2525

  3. Recommendations by the Spanish Society of Rheumatology on risk management of biological treatment and JAK inhibitors in patients with rheumatoid arthritis

    Reumatologia Clinica, Vol. 19, Núm. 10, pp. 533-548

2022

  1. Novel genes and sex differences in COVID-19 severity

    Human molecular genetics, Vol. 31, Núm. 22, pp. 3789-3806

2021

  1. Invasive fusariosis in nonneutropenic patients, Spain, 2000-2015

    Emerging Infectious Diseases, Vol. 27, Núm. 1, pp. 26-35

  2. Multicentre, randomised, open-label, phase IV-III study to evaluate the efficacy of cloxacillin plus fosfomycin versus cloxacillin alone in adult patients with methicillin-susceptible Staphylococcus aureus bacteraemia: Study protocol for the SAFO trial

    BMJ Open, Vol. 11, Núm. 8

2017

  1. High vancomycin MICs predict the development of infective endocarditis in patients with catheter-related bacteraemia due to methicillin-resistant Staphylococcus aureus

    Journal of Antimicrobial Chemotherapy, Vol. 72, Núm. 7, pp. 2102-2109

  2. Ventilator-associated pneumonia by methicillin-susceptible Staphylococcus aureus: do minimum inhibitory concentrations to vancomycin and daptomycin matter?

    European Journal of Clinical Microbiology and Infectious Diseases, Vol. 36, Núm. 9, pp. 1569-1575